Impact of ceftazidime avibactam on colonization by carbapenem resistant Enterobacterales during treatment of related infections

Abstract Carbapenem-resistant Enterobacterales (CRE), particularly carbapenem-resistant Klebsiella pneumoniae (CRKP) and carbapenem-resistant Escherichia coli (CREC), are significant pathogens causing healthcare-associated infections. This retrospective study assesses the effectiveness of ceftazidim...

Full description

Saved in:
Bibliographic Details
Main Authors: Uğur Önal, Ülkü Tüzemen, Pınar Küçükdemirci Kaya, Deniz Mercan, Funda Aslan, Gül Çalışkan, Remzi İşçimen, Cüneyt Özakın, Halis Akalın
Format: Article
Language:English
Published: Nature Portfolio 2025-08-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-025-14817-z
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849763718212091904
author Uğur Önal
Ülkü Tüzemen
Pınar Küçükdemirci Kaya
Deniz Mercan
Funda Aslan
Gül Çalışkan
Remzi İşçimen
Cüneyt Özakın
Halis Akalın
author_facet Uğur Önal
Ülkü Tüzemen
Pınar Küçükdemirci Kaya
Deniz Mercan
Funda Aslan
Gül Çalışkan
Remzi İşçimen
Cüneyt Özakın
Halis Akalın
author_sort Uğur Önal
collection DOAJ
description Abstract Carbapenem-resistant Enterobacterales (CRE), particularly carbapenem-resistant Klebsiella pneumoniae (CRKP) and carbapenem-resistant Escherichia coli (CREC), are significant pathogens causing healthcare-associated infections. This retrospective study assesses the effectiveness of ceftazidime-avibactam (CAZ/AVI) in achieving perianal swab (PAS) negativity compared to other treatments, including colistin, polymyxin B, meropenem, and combinations with fosfomycin. We retrospectively analyzed 147 CRE-colonized patients (76 females) screened with PAS samples from January 14, 2021, to April 27, 2024. Patients were divided into two groups: those treated with CAZ/AVI (n = 40) and those receiving alternative treatments (n = 44) for bloodstream infections or ventilator associated pneumonia caused by CRE. PAS negativity was defined as conversion from positive to negative, while relapse was a positive PAS result after initial negativity. A p-value below 0.05 was considered to be statistically significant. The CAZ/AVI group achieved a higher rate of PAS negativity (32 patients) with a median time to PAS negativity of 1 week. Relapse rates were similar between CAZ/AVI (23/24) and non-CAZ/AVI groups (8/10). Significant differences in PAS negativity were observed at two weeks (p < 0.001) but not at four weeks (p = 0.492). The median time to PAS negativity was shorter in the CAZ/AVI group (1 week) compared to the non-CAZ/AVI group (2 weeks; p = 0.027). CAZ/AVI is more effective than alternative treatments for short-term PAS negativity, but relapse rates are comparable, highlighting challenges in long-term CRE management. Continuous surveillance and personalized decolonization strategies are essential. Further research is needed to investigate relapse mechanisms and evaluate combination therapies or novel strategies for sustained decolonization.
format Article
id doaj-art-8bc7dc53a2674f058569054aedd7a369
institution DOAJ
issn 2045-2322
language English
publishDate 2025-08-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj-art-8bc7dc53a2674f058569054aedd7a3692025-08-20T03:05:18ZengNature PortfolioScientific Reports2045-23222025-08-011511610.1038/s41598-025-14817-zImpact of ceftazidime avibactam on colonization by carbapenem resistant Enterobacterales during treatment of related infectionsUğur Önal0Ülkü Tüzemen1Pınar Küçükdemirci Kaya2Deniz Mercan3Funda Aslan4Gül Çalışkan5Remzi İşçimen6Cüneyt Özakın7Halis Akalın8Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Bursa Uludağ UniversityFaculty of Medicine, Department of Medical Microbiology, Bursa Uludağ UniversityFaculty of Medicine, Department of Anesthesiology and Reanimation, Bursa Uludağ UniversityFaculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Bursa Uludağ UniversityFaculty of Medicine, Bursa Uludağ University, Infection Control Committee, Infection Control NurseFaculty of Medicine, Bursa Uludağ University, Infection Control Committee, Infection Control NurseFaculty of Medicine, Department of Anesthesiology and Reanimation, Bursa Uludağ UniversityFaculty of Medicine, Department of Medical Microbiology, Bursa Uludağ UniversityFaculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Bursa Uludağ UniversityAbstract Carbapenem-resistant Enterobacterales (CRE), particularly carbapenem-resistant Klebsiella pneumoniae (CRKP) and carbapenem-resistant Escherichia coli (CREC), are significant pathogens causing healthcare-associated infections. This retrospective study assesses the effectiveness of ceftazidime-avibactam (CAZ/AVI) in achieving perianal swab (PAS) negativity compared to other treatments, including colistin, polymyxin B, meropenem, and combinations with fosfomycin. We retrospectively analyzed 147 CRE-colonized patients (76 females) screened with PAS samples from January 14, 2021, to April 27, 2024. Patients were divided into two groups: those treated with CAZ/AVI (n = 40) and those receiving alternative treatments (n = 44) for bloodstream infections or ventilator associated pneumonia caused by CRE. PAS negativity was defined as conversion from positive to negative, while relapse was a positive PAS result after initial negativity. A p-value below 0.05 was considered to be statistically significant. The CAZ/AVI group achieved a higher rate of PAS negativity (32 patients) with a median time to PAS negativity of 1 week. Relapse rates were similar between CAZ/AVI (23/24) and non-CAZ/AVI groups (8/10). Significant differences in PAS negativity were observed at two weeks (p < 0.001) but not at four weeks (p = 0.492). The median time to PAS negativity was shorter in the CAZ/AVI group (1 week) compared to the non-CAZ/AVI group (2 weeks; p = 0.027). CAZ/AVI is more effective than alternative treatments for short-term PAS negativity, but relapse rates are comparable, highlighting challenges in long-term CRE management. Continuous surveillance and personalized decolonization strategies are essential. Further research is needed to investigate relapse mechanisms and evaluate combination therapies or novel strategies for sustained decolonization.https://doi.org/10.1038/s41598-025-14817-zCarbapenem-resistant EnterobacteralesCeftazidime-avibactamPerianal swab negativityDecolonizationIntensive care unit
spellingShingle Uğur Önal
Ülkü Tüzemen
Pınar Küçükdemirci Kaya
Deniz Mercan
Funda Aslan
Gül Çalışkan
Remzi İşçimen
Cüneyt Özakın
Halis Akalın
Impact of ceftazidime avibactam on colonization by carbapenem resistant Enterobacterales during treatment of related infections
Scientific Reports
Carbapenem-resistant Enterobacterales
Ceftazidime-avibactam
Perianal swab negativity
Decolonization
Intensive care unit
title Impact of ceftazidime avibactam on colonization by carbapenem resistant Enterobacterales during treatment of related infections
title_full Impact of ceftazidime avibactam on colonization by carbapenem resistant Enterobacterales during treatment of related infections
title_fullStr Impact of ceftazidime avibactam on colonization by carbapenem resistant Enterobacterales during treatment of related infections
title_full_unstemmed Impact of ceftazidime avibactam on colonization by carbapenem resistant Enterobacterales during treatment of related infections
title_short Impact of ceftazidime avibactam on colonization by carbapenem resistant Enterobacterales during treatment of related infections
title_sort impact of ceftazidime avibactam on colonization by carbapenem resistant enterobacterales during treatment of related infections
topic Carbapenem-resistant Enterobacterales
Ceftazidime-avibactam
Perianal swab negativity
Decolonization
Intensive care unit
url https://doi.org/10.1038/s41598-025-14817-z
work_keys_str_mv AT uguronal impactofceftazidimeavibactamoncolonizationbycarbapenemresistantenterobacteralesduringtreatmentofrelatedinfections
AT ulkutuzemen impactofceftazidimeavibactamoncolonizationbycarbapenemresistantenterobacteralesduringtreatmentofrelatedinfections
AT pınarkucukdemircikaya impactofceftazidimeavibactamoncolonizationbycarbapenemresistantenterobacteralesduringtreatmentofrelatedinfections
AT denizmercan impactofceftazidimeavibactamoncolonizationbycarbapenemresistantenterobacteralesduringtreatmentofrelatedinfections
AT fundaaslan impactofceftazidimeavibactamoncolonizationbycarbapenemresistantenterobacteralesduringtreatmentofrelatedinfections
AT gulcalıskan impactofceftazidimeavibactamoncolonizationbycarbapenemresistantenterobacteralesduringtreatmentofrelatedinfections
AT remziiscimen impactofceftazidimeavibactamoncolonizationbycarbapenemresistantenterobacteralesduringtreatmentofrelatedinfections
AT cuneytozakın impactofceftazidimeavibactamoncolonizationbycarbapenemresistantenterobacteralesduringtreatmentofrelatedinfections
AT halisakalın impactofceftazidimeavibactamoncolonizationbycarbapenemresistantenterobacteralesduringtreatmentofrelatedinfections